CGL
VRTX icon

Clarius Group LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

Clarius Group LLC’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$446K Sell
983
-4
-0.4% -$1.72K 0.03% 224
2025
Q3 		$387K Sell
987
-638
-39% -$267K 0.02% 247
2025
Q2 		$723K Sell
1,625
-193
-11% -$88.9K 0.04% 188
2025
Q1 		$881K Buy
1,818
+440
+32% +$205K 0.06% 158
2024
Q4 		$555K Sell
1,378
-130
-9% -$60.3K 0.04% 203
2024
Q3 		$700K Sell
1,508
-48
-3% -$23.1K 0.05% 162
2024
Q2 		$729K Sell
1,556
-94
-6% -$40.8K 0.05% 158
2024
Q1 		$690K Sell
1,650
-308
-16% -$130K 0.05% 173
2023
Q4 		$797K Sell
1,958
-127
-6% -$46.9K 0.07% 157
2023
Q3 		$725K Sell
2,085
-415
-17% -$145K 0.07% 156
2023
Q2 		$880K Buy
2,500
+48
+2% +$16.2K 0.07% 153
2023
Q1 		$773K Sell
2,452
-110
-4% -$33K 0.07% 169
2022
Q4 		$740K Buy
2,562
+62
+2% +$18.9K 0.07% 175
2022
Q3 		$724K Buy
2,500
+64
+3% +$18.4K 0.07% 161
2022
Q2 		$686K Buy
2,436
+316
+15% +$84.6K 0.07% 174
2022
Q1 		$466K Hold
2,120
– – 0.04% 254
2021
Q4 		$466K Sell
2,120
-76
-3% -$14.8K 0.04% 254
2021
Q3 		$398K Buy
2,196
+85
+4% +$16.6K 0.04% 260
2021
Q2 		$426K Sell
2,111
-23
-1% -$4.81K 0.04% 243
2021
Q1 		$459K Buy
2,134
+320
+18% +$70.3K 0.05% 207
2020
Q4 		$429K Buy
1,814
+132
+8% +$30.3K 0.05% 194
2020
Q3 		$458K Sell
1,682
-27
-2% -$7.45K 0.06% 149
2020
Q2 		$496K Buy
1,709
+155
+10% +$42K 0.07% 136
2020
Q1 		$370K Buy
1,554
+103
+7% +$23.6K 0.07% 148
2019
Q4 		$340K Buy
1,451
+43
+3% +$8.7K 0.05% 185
2019
Q3 		$239K Buy
+1,408
New +$249K 0.04% 238
2019
Q2 		– Sell
-1,152
Closed -$212K – 270
2019
Q1 		$212K Buy
+1,152
New +$213K 0.05% 196

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Clarius Group LLC's VRTX Position: Q4 2025 in Review

Clarius Group LLC reduced its Vertex Pharmaceuticals (VRTX) stake by 0.41% in Q4 2025, selling an estimated $1.72K and leaving 983 shares worth $446K. The position accounts for 0.03% of the portfolio, ranked #224.

Clarius Group LLC first reported a position in VRTX in Q1 2019 and has held it in 27 quarters since. The position peaked at $881K in Q1 2025. 1,669 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Clarius Group LLC held 983 shares of Vertex Pharmaceuticals worth $446K as of Q4 2025.
  • Clarius Group LLC sold 4 Vertex Pharmaceuticals shares in Q4 2025, an estimated $1.72K.
  • Vertex Pharmaceuticals made up 0.03% of Clarius Group LLC's portfolio in Q4 2025, its #224 holding.
  • Clarius Group LLC first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 27 quarters since.
  • Clarius Group LLC's Vertex Pharmaceuticals position peaked at $881K in Q1 2025.
  • 1,669 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Clarius Group LLC's 13F filing for Q4 2025, filed 14 Jan 2026.